HYDROXICLOROQUINE

Authors

DOI:

https://doi.org/10.21527/2176-7114.2020.38.16-21

Keywords:

Hydroxychloroquine, Coronavirus, Therapy

Abstract

Hydrochloroquine (HCQ) is an analogue of chloroquine, which was designed for malaria therapy. Over the past few decades, the potential for application in other pathologies, such as autoimmune diseases, oncology and viral infections, has been observed. The latter group includes the challenge of the 2019 coronavirus pandemic (COVID-19), which has infected hundreds of thousands of people and resulted in thousands of deaths worldwide. At this juncture, the objective was to discuss the potential use of hydrochloroquine in coronovavirus infections. Through the collected data, it was observed that HCQ can inhibit viral replication due to its accumulation in the lysosome and cell golgi complex, presenting low cost and helping to stabilize critically ill patients with COVID-19. However, there is no evidence regarding its effectiveness as a prophylactic drug, there are several adverse reactions and clinical contraindications, so its use should be properly prescribed by a health professional. In addition, randomized, blinded, clinical trials of coronovirus treatments should be established, so that clinical protocols can be used appropriately for HCQ.

Author Biographies

Dany Geraldo Kramer, FACISA UFRN

Programa de Pós-Graduação em Saúde da Família – RENASF. UFRN

Geraldo Barroso Cavalcanti Junior, Faculdade de Farmácia. Universidade Federal do Rio Grande do Norte

Prof. Dr. Faculdade de Farmácia. Universidade Federal do Rio Grande do Norte

Nathalie de Sena Pereira, Universidade Potiguar. Natal, Brasil

Universidade Potiguar - Natal, Brasil

Published

2020-06-30

How to Cite

Kramer, D. G., Cavalcanti Junior, G. B., & Pereira, N. de S. (2020). HYDROXICLOROQUINE. Revista Contexto &Amp; Saúde, 20(38), 16–21. https://doi.org/10.21527/2176-7114.2020.38.16-21

Issue

Section

Covid-19